Normal weight promotes remission and low number of islet antibodies prolong the duration of remission in Type 1 diabetes

Diabetic Medicine

Volumn 21, Issue 5, 2004, Pages 447-455

  Scholin A ^a   Torn C ^b   Nystrom L ^g   Berne, C ^a   Arnqvist, H ^c   Blohme G ^d   Bolinder, J ^e   Eriksson, J W ^f   Kockum, I ^e   Landin Olsson, M ^b   Ostman J ^e   Karlsson, F A ^a   Sundkvist, G ^b   Bjork E ^h  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^d STOCKHOLM SÖDER HOSPITAL   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^g UMEÅ UNIVERSITY   (Sweden)

^h NONE

Author keywords

BMI; Islet antibodies; Remission; Type 1 DM; Young adults

Indexed keywords

INSULIN; PANCREAS ISLET CELL ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; BIOCHEMISTRY; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HOSPITAL DISCHARGE; HUMAN; IMMUNOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; KETOACIDOSIS; KETONURIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PREDICTION; REMISSION; SURVIVAL;

ADOLESCENT; ADULT; AUTOANTIBODIES; BODY MASS INDEX; BODY WEIGHT; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; LOGISTIC MODELS; MALE; PROSPECTIVE STUDIES; REMISSION INDUCTION; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 2342482358     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2004.01175.x     Document Type: Article

References (34)

1. Hramiak IM, Dupre J, Finegood DT. Determinants of clinical remission in recent-onset IDDM. Diabetes Care 1993; 16: 125-32.
2. Shah SC, Malone JI, Simpson NE. A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus. N Engl J Med 1989; 320: 550-4.
3. Scholin A, Berne C, Schvarcz E, Karlsson FA, Bjork E. Factors predicting clinical remission in adult patients with type 1 diabetes. J Intern Med 1999; 245: 155-62.
4. Ostman J, Arnqvist H, Blohme G, Lithner F, Littorin B, Nystrom L et al. Epidemiology of diabetes mellitus in Sweden. Results of the first year of a prospective study in the population age group 15-34 years. Acta Med Scand 1986; 220: 437-45.
5. World Health Organization (WHO) Study Group. Diabetes mellitus. Report of WHO study group. Technical report series no. 727, Geneva: WHO, 1985.
6. Olsson ML, Sundkvist G, Lernmark A. Prolonged incubation in the two-colour immunofluorescence test increases the prevalence and titres of islet cell antibodies in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1987; 30: 327-32.
7. Verge CF, Stenger D, Bonifacio E, Colman PG, Pilcher C, Bingley PJ et al. Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop. Diabetes 1998; 47: 1857-66.
8. Schatz DA, Rogers DG, Brouhard BH. Prevention of insulin-dependent diabetes mellitus: an overview of three trials. Cleve Clin J Med 1996; 63: 270-4.
9. Grubin CE, Daniels T, Toivola B, Landin-Olsson M, Hagopian WA, Li L et al. A novel radioligand binding assay to determine diagnostic accuracy of isoform-specific glutamic acid decarboxylase antibodies in childhood IDDM. Diabetologia 1994; 37: 344-50.
10. Falorni A, Ortqvist E, Persson B, Lernmark A. Radioimmunoassays for glutamic acid decarboxylase (GAD65) and GAD65 autoantibodies using 35S or 3H recombinant human ligands. J Immunol Meth 1995; 186: 89-99.
11. Gianani R, Rabin DU, Verge CF, Yu L, Babu SR, Pietropaolo M et al. ICA512 autoantibody radioassay. Diabetes 1995; 44: 1340-4.
12. Palmer JP, Asplin CM, Clemons P, Lyen K, Tatpari O, Raghu PK et al. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 1983; 222: 1337-9.
13. Kockum I, Wassmuth R, Holmberg E, Michelsen B, Lernmark A. HLA-DQ primarily confers protection and HLA-DR susceptibility in type I (insulin-dependent) diabetes studied in population-based affected families and controls. Am J Hum Genet 1993; 53: 150-67.
14. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992; 39: 225-35.
15. Kockum I, Sanjeevi CB, Eastman S, Landin-Olsson M, Dahlquist G, Lernmark A. Complex interaction between HLA DR and DQ in conferring risk for childhood type 1 diabetes. Eur J Immunogenet 1999; 26: 361-72.
16. Sanjeevi CB, Seshiah V, Moller E, Olerup O. Different genetic backgrounds for malnutrition-related diabetes and type 1 (insulin-dependent) diabetes mellitus in south Indians. Diabetologia 1992; 35: 283-6.
17. Graham J, Kockum I, Sanjeevi CB, Landin-Olsson M, Nystrom L, Sundkvist G et al. Negative association between type 1 diabetes and HLA DQB1*0602- DQA1*0102 is attenuated with age at onset Swedish Childhood Diabetes Study Group. Eur J Immunogenet 1999; 26: 117-27.
18. Pozzilli P. Immunotherapy in type 1 diabetes. Diabet Med 1988; 5: 734-8.
19. Littorin B. Ascertainment, risk factors, and problems with classification. The Diabetes Incidence Study in Sweden (DISS). Lund: Lunds University 2001.
20. Pundziute-Lycka A, Dahlquist G, Nystrom L, Arnqvist H, Bjork E, Blohme G et al. Type I diabetes in the 0-34-year group in Sweden. Diabetologia 2002; 45: 783-91.
21. Pozzilli P, Mesturino CA, Crino A, Gross TM, Jeng LM, Visalli N. Is the process of β-cell destruction in type 1 diabetes at time of diagnosis more extensive in females than in males? Eur J Endocrinol 2001; 145: 757-61.
22. Ortqvist E, Falorni A, Scheynius A, Persson B, Lernmark A. Age governs gender-dependent islet cell autoreactivity and predicts the clinical course in childhood IDDM. Acta Paediatr 1997; 86: 1166-71.
23. Blohme G, Nystrom L, Arnqvist HJ, Lithner F, Littorin B, Olsson PO et al. Male predominance of type 1 (insulin-dependent) diabetes mellitus in young adults: results from a 5-year prospective nationwide study of the 15-34-year age group in Sweden. Diabetologia 1992; 35: 56-62.
24. Borg H, Gottsater A, Landin-Olsson M, Fernlund P, Sundkvist G. High levels of antigen-specific islet antibodies predict future β-cell failure in patients with onset of diabetes in adult age. J Clin Endocrinol Metab 2001; 86: 3032-8.
25. Torn C, Landin-Olsson M, Lernmark A, Palmer JP, Arnqvist HJ, Blohme G et al. Prognostic factors for the course of β-cell function in autoimmune diabetes. J Clin Endocrinol Metab 2000; 85: 4619-23.
26. Bonfanti R, Bazzigaluppi E, Calori G, Riva MC, Viscardi M, Bognetti E et al. Parameters associated with residual insulin secretion during the first year of disease in children and adolescents with Type 1 diabetes mellitus. Diabet Med 1998; 15: 844-50.
27. Komulainen J, Knip M, Lounamaa R, Vahasalo P, Karjalainen J, Sabbah E et al. Poor β-cell function after the clinical manifestation of type 1 diabetes in children initially positive for islet cell specific autoantibodies. The Childhood Diabetes in Finland Study Group. Diabet Med 1997; 14: 532-7.
28. Sabbah E, Savola K, Kulmala P, Veijola R, Vahasalo P, Karjalainen J et al. Diabetes-associated autoantibodies in relation to clinical characteristics and natural course in children with newly diagnosed type 1 diabetes. The Childhood Diabetes In Finland Study Group. J Clin Endocrinol Metab 1999; 84: 1534-9.
29. Ludvigsson J, Samuelsson U, Beauforts C, Deschamps I, Dorchy H, Drash A et al. HLA-DR3 is associated with a more slowly progressive form of type 1 (insulin-dependent) diabetes. Diabetologia 1986; 29: 207-10.
30. Veijola R, Knip M, Reijonen H, Vahasalo P, Puukka R, Iionen J. Effect of genetic risk load defined by HLA-DQB1 polymorphism on clinical characteristics of IDDM in children. Eur J Clin Invest 1995; 25: 106-12.
31. Kampe O, Andersson A, Bjork E, Hallberg A, Karlsson FA. High-glucose stimulation of 64,000-Mr islet cell autoantigen expression. Diabetes 1989; 38: 1326-8.
32. Bjork E, Kampe O, Karlsson FA, Pipeleers DG, Andersson A, Hellerstrom C et al. Glucose regulation of the autoantigen GAD65 in human pancreatic islets. J Clin Endocrinol Metab 1992; 75: 1574-6.
33. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care 1990; 13: 610-30.
34. Borg H, Arnqvist H, Björk E, Bolinder J, Eriksson JW, Nyström L et al. Evaluation of the new ADA and WHO criteria for classification of diabetes mellitus in young adults people (15-34 yr) in the Diabetes Incidence Study in Sweden (DISS). Diabetologia 2003; 46: 173-181.